Skip to main content
    I

    Inhibikase Therapeutics Inc (IKT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.83
    +0.03 (+1.67%)

    Market Cap: $251.16M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(10/21)
    Avg Surprise
    -10.19%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.11
    Range$-0.12 - $-0.11
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.10-13.3%
    60d ago$-0.09-25.9%
    30d ago$-0.09-25.9%
    7d ago$-0.10-17.2%
    Current$-0.11
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.15
    Range$-0.15 - $-0.14
    2 analysts
    Revenue Consensus
    $214290
    Range$0 - $2M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.15---
    Sep 26EST
    		-$-0.11---
    Jun 26
    Reported Aug 11
    		$-0.11$-0.09-22.22%Miss+0.0%
    Mar 26
    Reported May 12
    		$-0.10$-0.09-5.67%Miss+36.6%
    Dec 25
    Reported Mar 26
    		$-0.09$-0.12+25.00%Beat+48.5%
    Sep 25
    Reported Nov 14
    		$-0.13$-0.13+0.00%Beat+80.0%
    Jun 25
    Reported Aug 14
    		$-0.11$-0.08-37.50%Miss+83.3%
    Mar 25
    Reported May 14
    		$-0.15$-0.09-66.67%Miss+79.5%
    Dec 24
    Reported Mar 26
    		$-0.17$-0.09-101.73%Miss+72.7%
    Sep 24
    Reported Nov 14
    		$-0.65$-0.48-35.42%Miss+24.4%
    Jun 24
    Reported Aug 14
    		$-0.66$-0.67+1.49%Beat+40.5%
    Mar 24
    Reported May 15
    		$-0.73$-0.79+7.59%Beat+24.0%
    Dec 23
    Reported Mar 27
    		$-0.64$-0.85+24.71%Beat-255.6%
    Sep 23
    Reported Nov 14
    		$-0.86$-1.12+23.21%Beat-377.8%
    Jun 23
    Reported Aug 14
    		$-1.11$-0.92-20.65%Miss-516.7%
    Mar 23
    Reported May 16
    		$-0.96$-0.90-6.67%Miss-433.3%
    Dec 22
    Reported Mar 30
    		$-0.18$-0.19+5.26%Beat+10.0%
    Sep 22
    Reported Nov 14
    		$-0.18$-0.18+0.00%Beat+0.0%
    Jun 22
    Reported Aug 12
    		$-0.18$-0.19+5.26%Beat+18.2%
    Mar 22
    Reported May 16
    		$-0.18$-0.17-5.88%Miss+30.8%
    Dec 21
    Reported Mar 31
    		$-0.20$-0.17-17.65%Miss-33.3%
    Sep 21
    Reported Nov 15
    		$-0.18$-0.14-28.57%Miss-125.0%
    Jun 21
    Reported Aug 16
    		$-0.22$-0.38+42.11%Beat-266.7%
    Mar 21
    Reported May 17
    		$-0.26N/AN/ABeat-403.9%
    Dec 20
    Reported Mar 31
    		$-0.15N/AN/ABeat-124.2%
    Sep 20
    Reported Dec 4
    		$-0.08$0.00N/AMiss-52.1%
    Jun 20
    Reported Sep 30
    		$-0.06$0.00N/AMiss+59.5%
    Mar 20
    Reported Jun 29
    		$-0.05$0.00N/AMiss+82.0%
    Dec 19
    Reported Mar 30
    		$-0.07$0.00N/AMiss+68.5%
    Sep 19
    Reported Dec 31
    		$-0.05$0.00N/AMiss+47.4%
    Jun 19
    Reported Sep 30
    		$-0.15$0.00N/AMiss-826.2%
    Mar 19
    Reported Jun 29
    		$-0.29$0.00N/AMiss-1103.8%
    Dec 18
    Reported Mar 30
    		$-0.21$0.00N/AMiss-
    Sep 18
    Reported Oct 16
    		$-0.10$0.00N/AMiss-
    Dec 17
    Reported Mar 30
    		$-0.02$0.00N/AMiss-
    Dec 16
    Reported Mar 30
    		$-0.02$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-4.30EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-52.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage13.63x
    Current Ratio15.82xQuick Ratio15.82x
    Trading Statistics
    Beta0.90Avg Volume685.44K
    52-Week High$2.6152-Week Low$1.33

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.90
    SMA 20$2.01
    SMA 50$2.25
    SMA 200$1.95
    EMA 10$1.90
    EMA 20$2.00
    EMA 50$2.12
    EMA 200$2.00

    MACD

    Line: -0.12Signal: -0.11Hist: -0.01

    ADX

    ADX: 37.1+DI: 8.4-DI: 26.1

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down96.0
    PSAR$1.87

    Bollinger Bands

    Upper Band$2.31
    Lower Band$1.71
    %B Position3008%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    34.3

    Momentum Oscillators

    Stoch %K18.3
    Stoch %D15.3
    Williams %R-70.7
    ROC (10d)-5.2%
    Momentum-0.10
    CCI (20d)-106.1
    MFI (14d)42.8

    Volatility Measures

    ATR (14d)$0.11(6.0%)
    StdDev (20d)0.15
    Hist Vol54.0%(High)

    Volume Flow

    VWAP$1.83
    OBV24.3M
    AD Line-43.0M
    CMF (20d)-0.162

    Volume Metrics

    Avg Vol (20d)711.7K
    Vol Ratio0.6x
    VWMA (20d)$2.03

    Pivot Points

    R3$2.02
    R2$1.94
    R1$1.87
    Pivot Point$1.79
    S1$1.73
    S2$1.65
    S3$1.58

    Advanced Oscillators

    TSI-33.75
    Ultimate Osc45.8
    KST-181.98

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$26,274$0$0$0$-195,979$79,569
    Cost of Revenue$0$0$36,811$0$0$0$6,567$0$0$0$6,568$0
    Gross Profit$0$0$-36,811$0$0$0$-6,567$0$0$0$-195,979$79,569
    Operating Expenses$21.05M$17.84M$13.78M$12.77M$10.83M$14.60M$12.93M$5.83M$5.05M$4.78M$4.21M$4.85M
    R&D$13.39M$10.84M$6.36M$7.65M$5.27M$10.51M$7.19M$4.19M$3.08M$2.75M$3.00M$3.23M
    SG&A$7.66M$7.38M$6.77M$5.61M$5.92M$5.25M$5.74M$1.64M$1.97M$2.03M$1.40M$1.62M
    Operating Income$-21,050,995$-17,841,919$-13,775,626$-12,768,373$-10,832,278$-14,598,006$-12,928,697$-5,827,476$-5,050,535$-4,782,360$-4,403,566$-4,768,876
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-1,459,764$-1,461,079$-1,040,975$-838,093$-916,755$-919,271$-796,120$-49,410$-90,927$-132,725$-225,626$-173,677
    Income Before Tax$-19,591,231$-16,380,840$-12,770,932$-11,930,280$-9,917,500$-13,678,735$-12,168,025$-5,778,066$-4,959,608$-4,652,312$-4,011,975$-4,593,628
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-19,591,231$-16,380,840$-12,734,651$-11,930,280$-9,915,523$-13,678,735$-12,132,577$-5,778,066$-4,959,608$-4,649,635$-4,177,940$-4,595,199
    EBITDA$-21,050,995$-17,841,919$-13,775,626$-12,744,686$-10,810,097$-14,585,352$-12,922,130$-5,820,908$-5,043,966$-4,778,469$-4,396,998$-4,760,722
    EBIT$-21,050,995$-17,841,919$-13,775,626$-12,768,373$-10,834,255$-14,598,006$-12,928,697$-5,827,476$-5,050,535$-4,785,037$-4,403,566$-4,767,305
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IKT

    News

    Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to "Hold" at Chardan Capital

    Chardan Capital has upgraded Inhibikase Therapeutics (NASDAQ:IKT) to a "Hold" rating, though the overall analyst sentiment remains a "Moderate Buy" with a consensus target price of $4.75. The company's stock opened down...

    MarketBeat•10/14/26•Somewhat-Bearish

    Chardan initiates Inhibikase Therapeutics stock with neutral rating

    Chardan has initiated coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Neutral rating and a $1.50 price target...

    Investing.com•10/13/26•Somewhat-Bearish

    Chardan Initiates Inhibikase Therapeutics at Neutral With $1.50 Price Target

    Chardan has initiated coverage on Inhibikase Therapeutics (IKT) with a "Neutral" rating and set a price target of $1.50. The article notes that Inhibikase Therapeutics currently holds an average rating of "buy"...

    Yahoo Finance•10/13/26•Neutral

    Chardan initiates Inhibikase Therapeutics stock with neutral rating By Investing.com

    Chardan has initiated coverage on Inhibikase Therapeutics Inc (NASDAQ:IKT) with a Neutral rating and a price target of $1.50...

    Investing.com Nigeria•10/13/26•Neutral

    Inhibikase Therapeutics Inc (IQT0.SG) stock price, news, quote and history

    This article provides stock information for Inhibikase Therapeutics Inc (IQT0.SG), showing its current price of 3.2700 EUR with no change...

    Yahoo Finance UK•10/11/26•Neutral

    IKT Valuation and Fair Value

    P/E
    -4.3x
    P/B
    2.1x
    See GNG's fair value

    IKT Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -52.0%

    IKT Competitors

    CompanyTicker
    Vanda Pharmaceuticals IncVNDA
    Century Therapeutics IncIPSC
    OraSure Technologies IncOSUR
    BioAge Labs, IncBIOA
    EyePoint, IncEYPT
    So-Young International IncSY
    Prelude Therapeutics IncPRLD
    Bicycle Therapeutics LtdBCYC

    Sector: Healthcare

    IKT Analyst Ratings

    Consensus
    Buy
    Analysts
    9
    Strong Buy
    1
    Buy
    8
    Hold
    0
    Sell
    0
    Strong Sell
    0

    IKT Bull Case vs Bear Case

    Bull case

    • 100.0% of IKT's analyst ratings are Buy or Strong Buy.

    Bear case

    • IKT beat EPS estimates in 12.5% of its last 8 reported quarters.
    • IKT's quarterly revenue changed -100.0% year over year.

    IKT Earnings: Beat Rate and Next Report

    Beat rate
    1 of 8 quarters (12.5%)
    Average surprise
    -30.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.11
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About IKT

    Does IKT pay dividends?

    Inhibikase Therapeutics Inc (IKT) does not currently pay a regular dividend.

    What is IKT's market cap?

    Inhibikase Therapeutics Inc (IKT) has a market capitalization of $251.16M with a current stock price of $1.83.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In